Xenetic (XBIO) Biosciences has entered into a Clinical Trial Services Agreement with PeriNess to advance the company’s development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies. Under the terms of the Agreement, PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XBIO:
- Xenetic presents preclinical data on DNase I with CAR T cells in murine model
- Xenetic reports Q3 EPS (28c) vs. (69c) last year
- Xenetic presents preclinical data on DNase platform technology
- Xenetic Biosciences Expands Collaboration for Cancer Treatment
- Xenetic extends research collaboration with Scripps Research Institute
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
